Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Glioblastoma (GBM) is the most common primary adult brain tumor, characterized by extensive cellular and genetic heterogeneity. Even with surgery, standard chemotherapy, and radiation, tumor recurrence and patient relapse are inevitable with a median survival rate of <15 months. The overall goal of this proposal is to identify new therapeutic targets that drive clonal evolution in treatment-refractory GBM, develop novel and empirical immunotherapies that harness the immune system and target specific cell surface receptors on GBM cells at the same time, and undertake preclinical evaluation of candidate therapeutic antibodies using our unique animal model of human GBM recurrence. The interns in this proposed cluster will be involved in 1) tracking GBM cell populations to determine the intracellular pathways that drive relapse and 2) the development of novel biologics to target specific proteins in these pathways under the direction of Dr. Moffat (UofT) as well as 3) testing these in animal models in Dr. Singhs lab (McMaster). A promising lead panel of biotherapeutics will be translated into early clinical development at the partner organization, CCAB, and their its network of clinicians and industry partners with the hope of generating targeted therapies
Sheila Kumari Singh
Nicolas Yelle
Centre for the Commercialization of Antibodies and Biologics
Medicine
Life sciences
University of Toronto
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.